Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1198-1207

  Harris, Lyndsay N ^a,g   You, Fanglei ^a   Schnitt, Stuart J ^b   Witkiewicz, Agnes ^b   Lu, Xin ^a,c   Sgroi, Dennis ^d   Ryan, Paula D ^d   Come, Steven E ^b   Burstein, Harold J ^a,e   Lesnikoski, Beth Ann ^e   Kamma, Madhavi ^a,e   Friedman, Paula N ^f   Gelman, Rebecca ^a,c   Iglehart, J Dirk ^a,e   Winer, Eric P ^a,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Abbott Molecular Inc   (United States)

^g YALE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; NAVELBINE; RNA; SOMATOMEDIN C; TRASTUZUMAB;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GENE CLUSTER; HEART DISEASE; HUMAN; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PNEUMONIA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIDE EFFECT; STOMATITIS; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RECEPTOR, ERBB-2; VINBLASTINE;

EID: 33947246109     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1304     Document Type: Article

References (57)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
4. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92: 1991-8.
5. Yamauchi H, O'Neill A, Gelman R. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25.
6. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
7. Harris L, Luftner D, Jager W, Robertson JF. c-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999;14:8-15.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
10. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
11. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27:21-5: discussion 92-100.
12. Konecny G, Pegram MD, Beryt M, Untch M, Slamon DJ. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999;57:114.
13. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:58-66.
14. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
15. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
16. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21: 2889-95.
17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-84.
18. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
19. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676-85.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
21. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
22. van't Veer L, Dai H, van de Vijver M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
23. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11: 5678-85.
24. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
25. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
26. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-26.
27. Therasse P, Arbuck SG, Eisenhauer EA: European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
28. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
29. Cox DR. Analysis of binary data. London: Methuen and Co. Ltd.; 1970. p. 14-29.
30. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98: 31-6.
31. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002;7:410-7.
32. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
33. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24:1831-8.
34. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94:2169-73.
35. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression, and steroid hormone receptor status in human breast tumours. Anticancer Res 1996;16:3105-10.
36. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
37. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
38. Bacus S, Beresford P, Yarden Y, Spector N, Smith B. The use of predicting factors and surrogate markers in patients' cancer biopsies treated with targeted antibodies to erbB receptors and erbB tyrosine kinase inhibitors. Proc Am Soc Clin Oncol 2003;22:848.
39. Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698-706.
40. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91: 1532-42.
41. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54: 2771-7.
42. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-7.
43. You F, Harris LN. Molecular mechanisms of response and resistance to trastuzumab in HER2-overexpressing breast cancer. Biol Ther Breast Cancer 2004;5.
44. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28.
45. Neve RM, Holbro T, Hynes NE. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase, and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002;21: 4567-76.
46. Peyrat JP, Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 1992; 22:59-67.
47. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-60.
48. Frankenberry KA, Skinner H, Somasundar P, McFadden DW, Vona-Davis LC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 2006;28:985-93.
49. Yee D, Paik S, Lebovic GS, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-17.
50. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992; 22:21-9.
51. Seslar SP, Nakamura T, Byers SW. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 1993;53:1233-8.
52. Kerbel RS, St. Croix B, Florenes VA, Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell 1996;9:257-64.
53. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000;19:4337-45.
54. Vaage J. Fibrosis in immune control of mammary-tumor growth. Int J Cancer 1992;51:325-8.
55. McKay DB, Vazquez MA, Redline RW, Lu CY. Macrophage functions are regulated by murine decidual and tumor extracellular matrices. J Clin Invest 1992; 89:134-42.
56. Li DW, Liu JP, Mao YW, et al. Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by αB-crystallin through inhibition of RAS activation. Mol Biol Cell 2005;16:4437-53.
57. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15.